Neovasc Inc.
13700 Mayfield Place
Suite 2135
Richmond
British Columbia
V6V 2E4
Canada
Tel: 604-270-4344
Fax: 604-270-4384
Website: http://www.neovasc.com/
Email: info@neovasc.com
379 articles about Neovasc Inc.
-
Micro Interventional Devices, Inc. Reaches Settlement Agreement with Neovasc, Inc.
2/20/2019
Micro Interventional Devices, Inc. announced that it is has entered into a Settlement Agreement with Neovasc, Inc.
-
Neovasc Provides Corporate Update
2/20/2019
Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today provided a corporate and operational update.
-
Pierangeli Clinic Initiates Program Providing Neovasc Reducer™ Procedure to Italian Patients with Refractory Angina
2/11/2019
Second U.S. patient successfully undergoes Reducer procedure under compassionate use
-
Neovasc Announces Renewal of German NUB Status 1 Designation for Neovasc Reducer Procedure for Treatment of Refractory Angina
1/30/2019
Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure
-
Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK
1/29/2019
Successfully completed all Phase 1 requirements of TIARA-II
-
Neovasc announces peer reviewed publication in JACC demonstrating objective evidence of improvement in perfusion after Reducer implantation
1/23/2019
Neovasc Inc. today announced that the Journal of the American College of Cardiology: Cardiovascular Interventions ("JACC") published a peer reviewed article on the use of dipyridamole stress perfusion cardiac magnetic resonance ("CMR") to assess the performance of its Neovasc Reducer™
-
Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
1/14/2019
Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX:NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market.
-
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
1/4/2019
Neovasc announced today that it has received written notification notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market.
-
Neovasc Receives ISO 13485: 2016 Certification
12/21/2018
Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has received ISO 13485:2016 certification,
-
Neovasc Announces Positive 12-year Follow-up Data for Neovasc Reducer; as Published in JACC
12/11/2018
The publication is entitled: "First-in-Human Use of Coronary Sinus Reducer in Patients With Refractory Angina."
-
JACC: Cardiovascular Interventions Publishes Peer Reviewed Article on Neovasc Reducer Patient Case
11/20/2018
Neovasc Inc. today announced that the Journal of the American College of Cardiology: Cardiovascular Interventions published a peer reviewed article on the clinical response of a patient that received the Neovasc Reducer™ (the "Reducer"), a medical device for the treatment of refractory angina, titled, "Coronary Sinus Reducer Implantation to Reduce the Ischemic Burden in Refractory Angina."
-
Neovasc Announces Third Quarter 2018 Financial Results
11/14/2018
FDA has granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment of refractory angina
-
Neovasc Announces Third Quarter 2018 Financial Results Conference Call and Webcast
11/7/2018
Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and nine months ended September 30, 2018 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, November 14, 2018.
-
Neovasc Announces Successful Tiara™ "Live Case" at the 32nd Annual EACTS 2018 Meeting
10/22/2018
Neovasc Inc. today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 32nd Annual European Association for Cardio-Thoracic Surgery Meeting ("EACTS 2018"), held October 18-20 in Milan, Italy.
-
Neovasc Announces Publication of a Peer-Reviewed Article on Tiara Cases in Circulation: Cardiovascular Interventions
10/16/2018
Accompanying editorial comment also published by the journal
-
Neovasc Reducer™ Granted Breakthrough Device Designation from FDA
10/10/2018
Neovasc Inc. today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Device designation to the Neovasc Reducer™
-
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
10/9/2018
Neovasc, Inc announced today that it has received written notification from the Nasdaq Hearings Panel (the "Panel") notifying the Company that it has regained compliance
-
Neovasc Announces Positive 12-week Follow-up Data from the First U.S. Patient Implanted with a Neovasc Reducer
10/3/2018
The Compassionate Use case was conducted in June 2018.
-
Neovasc's Tiara and Reducer to be Featured at TCT 2018 Conference
9/20/2018
Both will be featured in several presentations at the Transcatheter Cardiovascular Therapeutics 2018 scientific symposium to take place September 21-25, 2018 in San Diego, California.
-
Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany
9/19/2018
Neovasc, Inc. announced today that a Neovasc Reducer™ (the "Reducer") has now been implanted in 100 patients in Germany. The Reducer is a wire mesh implanted into a vein in the heart which treats patients with refractory angina.